Search Results for "michigan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for michigan. Results 201 to 210 of 308 total matches.
Preservation of Ovarian Function During Chemotherapy
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
University College of Physicians and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan ...
Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility
counseling followed by appropriate action may prevent some of these undesirable consequences.
A Sumatriptan Needle-Free Injector for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
David N ...
Sumatriptan was first marketed in the US in 1993 as Imitrex for subcutaneous injection, followed by tablets for oral administration and then by a nasal spray. It is one of seven serotonin receptor agonists (“triptans”) marketed in the US for treatment of migraine, but it is the only one available for subcutaneous injection. Now the FDA has approved Sumavel DosePro> (Zogenix), a needle-free device for delivering sumatriptan succinate to subcutaneous tissue, for treatment of migraine and cluster headache in adults.
Another Insulin Glargine (Basaglar) for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 02, 2017 (Issue 1511)
. Dalton, M.D., M.P.H., University of Michigan Medical School;
Eric J. Epstein, M.D., Albert Einstein ...
The FDA has approved Basaglar (Lilly/Boehringer
Ingelheim), a "follow-on" 100 units/mL insulin glargine
product similar to Lantus (Sanofi), which recently
went off patent. A 300 units/mL formulation of insulin
glargine (Toujeo) was approved in 2015.
RotaTeq: A New Oral Rotavirus Vaccine
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006 (Issue 1240)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
SENIOR ...
The FDA has recently approved RotaTeq (Merck), an oral live, human-bovine reassortant rotavirus vaccine, for use in infants to prevent rotavirus gastroenteritis, a frequent cause of severe diarrhea in infancy.
Naltrexone (Vivitrol) - A Once Monthly Injection for Alcoholism
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006 (Issue 1240)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
SENIOR ...
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone (Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to maintain abstinence from alcohol. Naltrexone inhibits the rewarding effects of alcohol. Oral naltrexone (Revia, and others) has been approved for treatment of alcohol dependence since 1994, but poor adherence has limited its effectiveness. In the new extended-release (XR) formulation, naltrexone is encapsulated in polylactide-co-glycolide microspheres (similar to absorbable suture material)...
Intravenous Ibandronate (Boniva)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein ...
Ibandronate (Boniva - Roche) is the first bisphosphonate approved by the FDA for intravenous (IV) treatment of osteoporosis in postmenopausal women. It is given as a bolus injection once every 3 months. Ibandronate is also available as an oral once-a-month 150-mg tablet and as a daily 2.5-mg tablet.
Darunavir (Prezista) for HIV Infection
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
Darunavir (Prezista - Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency virus (HIV) infection in previously treated adults. It is coadministered with low-dose ritonavir (Norvir), which increases its bioavailability.
Three New Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006 (Issue 1244)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.
Dasatinib (Sprycel) for CML and Ph+ ALL
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007 (Issue 1252)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein ...
Dasatinib (Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults.
Pioglitazone/Glimepiride (Duetact) for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
Duetact (Takeda), a new fixed-dose combination of the thiazolidinedione pioglitazone (Actos) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved as an adjunct to diet and exercise to improve glycemic control in patients already taking pioglitazone and/or a sulfonylurea. Avandaryl, a combination of glimepiride and the thiazolidinedione rosiglitazone, was approved in 2006.